Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1984 2
1985 3
1986 6
1987 8
1988 2
1989 7
1990 6
1991 3
1992 3
1993 2
1994 4
1995 2
1996 3
1997 2
1998 1
2001 1
2002 1
2003 1
2005 1
2006 1
2012 1
2014 1
2015 1
2020 1
2021 1
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

65 results
Results by year
Filters applied: . Clear all
Page 1
Targeting CXCR1/2 in the first multicenter, double-blinded, randomized trial in autologous islet transplant recipients.
Witkowski P, Wijkstrom M, Bachul PJ, Morgan KA, Levy M, Onaca N, Chaidarun SS, Gardner T, Shapiro AMJ, Posselt A, Ahmad SA, Daffonchio L, Ruffini PA, Bellin MD. Witkowski P, et al. Among authors: daffonchio l. Am J Transplant. 2021 Nov;21(11):3714-3724. doi: 10.1111/ajt.16695. Epub 2021 Jun 23. Am J Transplant. 2021. PMID: 34033222 Clinical Trial.
Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes.
Maffi P, Lundgren T, Tufveson G, Rafael E, Shaw JAM, Liew A, Saudek F, Witkowski P, Golab K, Bertuzzi F, Gustafsson B, Daffonchio L, Ruffini PA, Piemonti L; REP0211 Study Group. Maffi P, et al. Among authors: daffonchio l. Diabetes Care. 2020 Apr;43(4):710-718. doi: 10.2337/dc19-1480. Epub 2020 Feb 4. Diabetes Care. 2020. PMID: 32019854 Free PMC article. Clinical Trial.
CXCR1/2 inhibition enhances pancreatic islet survival after transplantation.
Citro A, Cantarelli E, Maffi P, Nano R, Melzi R, Mercalli A, Dugnani E, Sordi V, Magistretti P, Daffonchio L, Ruffini PA, Allegretti M, Secchi A, Bonifacio E, Piemonti L. Citro A, et al. Among authors: daffonchio l. J Clin Invest. 2012 Oct;122(10):3647-51. doi: 10.1172/JCI63089. Epub 2012 Sep 17. J Clin Invest. 2012. PMID: 22996693 Free PMC article. Clinical Trial.
CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice.
Citro A, Valle A, Cantarelli E, Mercalli A, Pellegrini S, Liberati D, Daffonchio L, Kastsiuchenka O, Ruffini PA, Battaglia M, Allegretti M, Piemonti L. Citro A, et al. Among authors: daffonchio l. Diabetes. 2015 Apr;64(4):1329-40. doi: 10.2337/db14-0443. Epub 2014 Oct 14. Diabetes. 2015. PMID: 25315007
Adrenergic-prostaglandin interactions in the respiratory system.
Omini C, Daffonchio L, Abbracchio MP, Hernandez A, Cattabeni F. Omini C, et al. Among authors: daffonchio l. Prostaglandins Leukot Essent Fatty Acids. 1990 Jun;40(2):85-91. doi: 10.1016/0952-3278(90)90149-f. Prostaglandins Leukot Essent Fatty Acids. 1990. PMID: 2166962 Review. No abstract available.
Ladarixin, an inhibitor of IL-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: a multicenter, randomized, double-blind, placebo-controlled trial.
Piemonti L, Keymeulen B, Gillard P, Linn T, Bosi E, Rose L, Pozzilli P, Giorgino F, Cossu E, Daffonchio L, Goisis G, Ruffini PA, Maurizi AR, Mantelli F, Allegretti M. Piemonti L, et al. Among authors: daffonchio l. Diabetes Obes Metab. 2022 May 19. doi: 10.1111/dom.14770. Online ahead of print. Diabetes Obes Metab. 2022. PMID: 35589610
65 results